Thus, TRAIL-R-targeted anti-cancer therapy in p53+/+ expressing cells involves the risk of promoting pro-survival and metastatic pathways in response to TRAIL or TRAIL-R-agonistic antibodies. This evidence concerns the gene TNFSF10 and cancer.